This is the authors' abstract. We don't add key points for this paper.
We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neoadjuvant carboplatin/nab-paclitaxel chemotherapy (CT) plus atezolizumab with CT alone in stage II/III triple-negative breast cancer. We also assessed the predictive function of the immuno-oncology (IO) score in expression data of patients treated with pembrolizumab plus paclitaxel (N = 29) or CT alone (N = 56) in the I-SPY2 trial.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dugo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: